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ABSTRACT
Over the past 20 years, Pulmonary Arterial Hypertension (PAH) patients and providers have seen an increase
in options to treat PAH. Currently, there are choices for the delivery of medications approved to treat patients with
PAH where at one point the only option was intravenous (IV) therapy. This case study details the transition from
IV Epoprostenol to oral Treprostinil for the treatment of a 53 year old female diagnosed with severe Pulmonary
Arterial Hypertension whose quality of life became unbearable by the IV medication delivery route. This patient
was a synchronized swimmer in her youth and her passion for water activities continued throughout her short life.
After her diagnosis of severe PAH, her life abruptly changed as she was placed on triple therapy, which consisted
of an endothelin receptor antagonist (ERA), a phosphodiesterase-5 inhibitor (pde-5), and the IV epoprostenol. The
patient experienced severe side effects that negatively impacted her ability to resume her activities of daily life and
swimming. Although she remained hemodynamically stable on IV therapy, her poor quality of life and severe depression convinced her cardiologist that transitioning to an oral treprostinil would be the only option for her survival. At the time, there was a lack of clinical trials or guidelines to support the transition from IV to oral prostacyclins to follow, so an interdisciplinary team approach needed to be taken to ensure that the safety and efficacy of
the transition would be maintained.
Keywords: Pulmonar y ar ter ial hyper tension (PAH), Tr ansition, Epopr ostenol, Tr epr ostinil, Quality of life
BACKGROUND
The World Health Organization has categorized
Pulmonary Hypertension into five groups: Pulmonary
Arterial Hypertension, Pulmonary Hypertension due to
left heart disease, Pulmonary Hypertension due to lung
disease, Pulmonary Hypertension due to chronic blood
clots in the lungs, and Pulmonary Hypertension due to
unknown causes (Pulmonary Hypertension Association, 2019). PAH is diagnosed during a right heart
catheterization and is characterized by the remodeling,
narrowing and elimination of pulmonary arteries
caused by endothelial cell proliferation, inflammation
of the vascular wall and fibrosis which elevates the
pulmonary pressures (Hambly, 2016 ). It is a rare but
serious condition affecting as few as 5 in 1 million
adults with a 5 year survival rate of just 37% as recorded in the 1980’s NIH registry (McLaughlin, 2013).

The associated symptoms are disabling to the patient
and include dyspnea, fatigue, syncope, and chest pain
leading to premature death due to their risk for developing right ventricular failure (Hambly, 2016 ).
It was Aminorex (Fen/phen), an appetite suppressant, which caused an epidemic of the disease in 1965
which led to the withdrawal of Fen/Phen from the market in 1997 (Anderson, 2016). It wasn’t until the
1990’s that a treatment care plan including warfarin in
combination with high dose calcium channel blockers
started being prescribed for the treatment of PH. Then,
a clinical trial demonstrated that the use of long-term
intravenous (IV) prostacyclin improved the hemodynamics and functional class in this patient population
(McLaughlin, 2013). Following the study of IV prostacyclins, inhaled and oral prostacyclins were investigated; in 2013, the Food and Drug Administration
(FDA) approved the first oral prostacyclin for the treat-
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ment of PAH (Anderson, 2016). The oral drug was in
development for 17 years and offered another route of
administration for patients requiring prostacyclin therapy (United Therapeutics, 2013). Currently, there are
14 approved medications for the treatment of PH. At
one point the treatment option for PH was exclusively
IV therapy but now the delivery options have expanded to include both oral and inhalation administration
routes.
More oral and inhaled prostacyclins or prostacyclin
analogs have become available in recent years. Recently successful transitions from IV prostacyclin to one of
the oral/inhaled equivalents have been reported, but at
the time of this report, there were no published guidelines to transition patients from IV epoprostenol to oral
treprostinil to refer to. Although both drugs are similar,
epoprostenol differs from treprostinil with its shorter
half –life, no greater than six minutes, and the absence
of an oral equivalent. Both drugs, independently, have
been shown to be effective in the treatment of pulmonary hypertension (Saito, 2015).
The use of central lines to deliver prostacyclin therapy comes with many expected side-effects as well as
complications. Flushing, sinus congestion, GI upset,
diarrhea, generalized edema, insertion site discomfort,
generalized pain, and headaches are the most common
side effects which effects patient’s quality of life
(Hanlon, 2017). It is reasonable that patients, like the
patient in this case study, who suffer with severe side
effects, experience a decrease in quality of life. The
treatment regimen for each patient is highly individualized according to the patient’s tolerance of each titration increase. The following case study details the
seven week transition schedule that was used to wean
the patient off of IV onto an oral treprostinil and challenges the healthcare team had to overcome to help
this patient achieve greater independence and better
quality of life.
CASE PRESENTATION
A 53-year-old female diagnosed with severe Pulmonary Arterial Hypertension by right heart catheterization in 2012. It is believed that this patient developed
PAH by using the appetite suppressant Fen-Phen. In
2012 the patient was placed on triple therapy which
included a phosphodiesterase inhibitor (PDE-5), an
endothelin receptor antagonist (ERA), and IV epoprostenol. The patient was referred to a PH specialist
for further evaluation and treatment. The patient experienced severe side-effects from the IV infusion in37
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cluding: pronounced facial flushing, sinus congestion,
GI upset, diarrhea, generalized edema, and headache.
Other complaints included central catheter pain, shortness of breath on exertion, depression, and continuous
oxygen dependence. The patient remained medically
stable on the IV therapy but due to the risk for line
infection, safety, and diminished quality of life, the
physician and patient decided to transition from the IV
epoprostenol to oral treprostinil.
Establishing a transition protocol from IV epoprostenol to oral treprostinil in the absence of clear
guidelines and in an outpatient setting was challenging.
A health care team consisting of a pharmacist, nurses,
cardiologist, pulmonologist, and drug manufacturer
RN representative were all consulted and contributed
to the patient’s titration schedule. Each specialty discussed treatment options and potential complications.
Once the choice of oral medication was identified, a
clinical pharmacist assembled a transition schedule
using contributions given by the planning team and
limited data which was available on the topic. The
weekly titrations were performed under the close observation of the cardiologist whether in the medical
office, at home with the drug RN representative, or in
the outpatient clinic which specializes in PH. The patient’s physical and mental status were discussed, evaluated, and well documented during the seven week
period. A slow transition schedule was used to accommodate the patient and secure her safety. The patient
was seen at the cardiologist office as well as the heart
failure outpatient clinic alternating weekly and had
phone access to all members of the team 24/7. The
dosing schedule using dual therapy during the seven
day titration period is shown in Table 1. The patient
was getting 20ng/kg/min of the IV epoprostenol prior
to the titration.
DISCUSSION
This case represents a difficult but successful transition from intravenous epoprostenol to oral treprostinil despite the lack of guidelines. The patient was able
to transition to oral treprostinil 14 mg/p.o./daily and
stayed medically stable. Furthermore, her exercise
tolerance increased and she was able to resume activities, such as swimming and other hobbies that were
prohibited once IV therapy had been initiated improving her quality of life and renewing her sense of hope.
Since this case study, there has been many successful
week-long transitions published with improved exercise tolerance and patient outcomes (Gleason, 2015).
Baptist Health South Florida
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Table 1
Epoprostenol IV to Treprostinil Oral Transition Schedule
Week
(Visit type)

Week 1
(Clinic)

Week 2
(Cardiologist office)

Week 3
(Clinic)

Week 4
(Cardiologist office)

Week 5
(Clinic)

Week 6
(Cardiologist office)

Week 7
(Clinic)

Oral Treprostinil Dose

IV
Epoprostenol

(# of tabs to administer)

Total Oral
Treprostinil
Dose

18 ng/kg/min

morning 0.125 mg (use 0.125 mg tab)
noon 0.125 mg (use 0.125 mg tab)
evening 0.125 mg (use 0.125 mg tab)

0.375 mg/po/day

14 ng/kg/min

morning 0.5mg (2 tabs of 0.25mg tab)
noon 0.5 mg (2 tabs of 0.25mg tab)
evening 0.5 mg (2 tabs of 0.25mg tab)

1.5 mg/po/ day

10 ng/kg/min

morning 1mg (4 tabs of 0.25mg tab)
noon 1 mg (4 tabs of 0.25mg tab)
evening 1 mg (4 tabs of 0.25mg tab)

3 mg/po/day

6 ng/kg/min

morning 2mg (2 tabs of 1mg tab)
noon 2 mg (2 tabs of 1mg tab)
evening 2 mg (2 tabs of 1mg tab)

6 mg/po/day

3 ng/kg/min

morning: 3.5 mg (2.5 mg tab+1 mg tab)
noon: 3.0 mg (2.5 mg tab+0.5 mg tab)
evening: 3.5mg (2.5 mg+1 mg tab )

10 mg/po/day

1.5 ng/kg/min

morning: 4 mg (2.5 mg tab+1 mg tab +0.25 tab+0.25 tab)
noon: 4 mg (2.5 mg tab+1 mg tab+0.25t ab+0.25 tab)
evening: 4.5 mg (2.5 mg tab+2 tabs of 1 mg tabs)

12.5 mg/po/day

Stop infusion

morning: 4 mg (2.5 mg tab+1 mg tab+2 tabs of 0.25mg tab)
noon: 5 mg (2 tabs of 2.5mg)
evening: 5 mg (2 tabs of 2.5mg)

14 mg/po/day

Similarly, there have been successful, safe, and cost
efficient transitions from IV epoprostenol to oral PH
prostacyclin therapies in the outpatient setting (Morris
KL, 2018). However, at the time of this case, the
healthcare team had to work very careful and diligently
regardless of the lack of treatment guidelines, to make
a quick decision to provide this patient with a meaningful and improved quality of life.
Currently, there are published criteria that identify

ideal candidates for IV to oral transitions. These patients have to show hemodynamic, clinical, and physiological signs of stability in order to achieve a successful transition (Coons, 2016; Sofer, 2017). This case
report does not provide data on the long-term success
from an IV epoprostenol to oral treprostinil transition,
however, this patient was able to transition and maintain her physiological status as well as report a better
quality of life.
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CONCLUSION

REFERENCES

This case study demonstrates that making sound
treatment decisions can be difficult at times but the
goal of the treatment can be accomplished with strong
collaboration, compassion, and respect for the individual’s quality of life. The transition incorporated the
expertise of the multidisciplinary team including the
pharmacist, nurses, cardiologist, pulmonologist, and
drug manufacturer’s RN representative in order to establish a safe plan of care that addressed the individual
needs of this patient. The best decision-making for
medical treatments is made when healthcare providers
take into account patients’ quality of life.

Anderson, R. M. (2016). Pulmonary hypertension:
evolution of pulmonary arterial hypertension
and chronic thromboembolic pulmonary hy
pertension. Journal of Thoracic Disease, S562
-S565.

DECLARATION OF INTEREST
The authors report no conflicts of interest. The
authors alone are responsible for the content and writing of the paper.
AUTHORS
Tina Hyman, MSN, RN-BC
Clinical Nurse Educator 1
South Miami Hospital Heart Rhythm Center
6200 SW 73 St. South Miami, Fl. 33143
Correspondence regarding
this paper can be directed at TinaH@baptisthealth.net
Michael Salinero, BSN, RN
Nurse Manager- Heart Rhythm Center
South Miami Hospital Heart Rhythm Center
6200 SW 73 St. South Miami, Fl. 33143
Francisco Javier Jimenez-Carcamo MD, PhD,
FACC.
Director of Advanced Heart Failure and Pulmonary
Hypertension
6200 Sunset Dr. Ste. 401
South Miami, Fl. 33143
Margarita Pallares, MSN, APRN, AGACNP-BC
Adult Gerontology Acute Care Nurse Practitioner
South Miami Hospital Heart Rhythm Center
6200 SW 73 St. South Miami, Fl. 33143
Maribel Matos, MSN, APRN, AANP-BC
Nurse Practitioner
South Miami Hospital Heart Rhythm Center
6200 SW 73 St. South Miami, FL. 33143

Badesch, D. (1997). Clinical trials in pulmonry hypertension. Annual review of medicine (00664219), 48, 399.
Coons, C. J. (2016). Oral treprostinil for the treatment
of arterial hypertension in patient transitioned
from parenteral or inhaled prostacyclins: Case
series and treatment protocol. Pulmonary Circulation, (6), 10.1086/685111.
Gleason, J. D. (2015). The Rapid Initiation, Titration,
and Transition from Intravenous to Oral
Treprostinil in a Patient with Severe Pulmonary Arterial Hypertension. Case Reports in
Pulmonology, doi: 10.1155/2015/498981.
Hambly, N. A. (2016 ). Pulmonary hypertension: diagnostic approach and optimal management.
CMAJ-JAMC 188 (11), 804-812.
Hanlon, P. (2017, 9 November). Managing Prostacyclin Side Effects. Retrieved from PHA: https://
phassociation.org/managing-prostacyclin-side
-effects/
McLaughlin, V. (2013). Managing pulmonary arterial
hypertension and optimizing treatment options: Prognosis of pulmonary artery hypertension. . The A merican Journal of Cardiology 111 (8).
Morris KL, K. A. (2018). Outpatient Transition of Parenteral to Oral Prostacyclin in Pulmonary
Arterial Hypertension. PHA Online University (p. 121). Orlando: Pulmonary Hypertension Association.
Pulmonary Hypertension Association. (2019). About
Pulmonary Hypertension: The WHO Groups.
Retrieved from PHA: https:/?phassociation.
org/types-pulmonary-hypertension-groups/
Saito, Y. N. (2015). Epoprostenol sodium for treatment
of pulmonary arterial hypertension. V ascular
Health Risk Management ; 11, 265-270.
Surapaneni, P. V. (2011). Valvular Heart Disease with

39

https://scholarlycommons.baptisthealth.net/nhsrj/vol2/iss1/8
DOI: 10.55481/2578-3750.1044

Baptist Health South Florida

39

Hyman et al.: Navigating a Difficult Transition in Pulmonary Arterial Hypertens

the Use of Fenfluramine-Phentermine. Texas
Heart Institute Journal, 38(5), 581-583.
United Therapeutics. (2013). United Therapeutics
Announces FDA Approval of Orenitram Extended Release Tablets for Pulmonary Arterial Hypertension Treatment - Final. Fair Disclosure Wire.

Nursing and Health Sciences Research Journal ·Vol 2, No 1, 2019

Published by Scholarly Commons @ Baptist Health South Florida, 2019

40

40

